INVENTORIES

6 Months Ended

Jun. 30, 2025

Inventory Disclosure [Abstract]

INVENTORIES

INVENTORIES

Inventories consist of the following as of:

(in thousands)	June 30, 2025		December 31, 2024
Raw materials	$	63,848	$	67,174
Packaging materials	9,932		9,977
Work-in-progress	4,898		1,665
Finished goods	59,637		57,966
Inventories	$	138,315	$	136,782

Vendor Concentration

Raw materials are sourced for products, including active pharmaceutical ingredients (“API”), from both domestic and international suppliers. Generally, only a single source of API is qualified for use in each product due to the cost and time required to validate a second source of supply. As a result, the Company is dependent upon our current vendors to reliably supply the API required for on-going product manufacturing. During the three months ended June 30, 2025, no single vendor represented more than 10% of our raw inventory purchases. During the six months ended June 30, 2025, approximately 23% of our raw material inventory purchases were from one domestic supplier. During the three and six months ended June 30, 2024, approximately 27% and 24%, respectively, of our raw material inventory purchases were from one domestic supplier.